LifeSci noted the combined company is expected to have approximately $60 million in cash at closing if shareholders approve the deal. Vincera shareholders will own approximately 40% of the issued and outstanding common stock of the combined company, excluding warrants. Read more.
LifeSci Files Prelim Proxy on Vincera Pharma Merger
